Table 5.

Six-month change (mean±SD) oral glucose tolerance test (OGTT) and lipid data in postmenopausal women treated with placebo, raloxifene, or hormone therapy (HT) who completed the intervention and OGTT visit.

	6-month Change
	Placebo	Raloxifene	HT
OGTT, n	27	33	33
GLU0, mmol/L	0.03±0.52	−0.02±0.85	0.35±0.61*
GLU120, mmol/L	−0.50±2.13	−0.04±2.30	−0.09±1.74
GLUA, *103	−0.86±2.42	−0.26±3.65	−0.46±2.79
INS0, pmol/L	−5.57±25.2	−16.5±26.2	−15.2±32.9
INS120, pmol/L	−51.0±181.5	−79.8±233.9	43.5±567.3
INSA, *103	−0.92±2.24	−1.17±3.13	−0.35±3.89
INSA* GLUA,*107	−2.16±4.12	−2.05±6.31	−0.52±8.60
Lipid profile, n	27	33	33
Total C, mmol/L	−0.14±0.85	−0.23±0.62	−0.18±0.68
TG, mmol/L	−0.26±0.47	−0.11±0.58	0.02±0.83
HDL-C, mmol/L	−0.09±0.27	0.09±0.17*	0.12±0.22*
LDL-C, mmol/L	0.03±0.74	−0.28±0.59*	−0.30±0.61*

0 subscript, fasting (0 min); 120 subscript, post-glucose challenge (120 min); A, area under the curve; C, cholesterol; GLU, glucose; HDL, high density lipoprotein; INS, insulin; LDL, low density lipoprotein;

^*p<0.05, different from placebo.